LGND News and Press, Ligand Pharmaceuticals Incorporated From 10/14/20

This article presents a list of stocks with the highest short interest as a percentage of shares outstanding. An unprecedented year amid the COVID-19 pandemic driving historic volatility has represented significant trading opportunities for short-sellers. We analyze key trends and...

Ligand Pharmaceuticals ([[LGND]] +1.3%) announces that it has sold its Vernalis research operations and internal programs to HitGen Inc. for $25M in cash.Ligand to retain economic rights on completed collaboration licenses as well as a share of the economic rights on current research collabor...

Consideration includes $25 million cash payment plus Ligand retains economics on completed partnerships and share of economics on current collaborations Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the sale of Ligand’s Vernalis research operati...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Company will be hosting a virtual Investor Day on Tuesday, October 20 th from 11:00 a.m. ET to approximately 1:00 p.m. ET. Presenting during the event will be: John Higgins, Chief Executive Officer Matt F...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractua...

Ligand Pharmaceuticals ([[LGND]] +5.0%) expects Captisol material sales of ~$200M in 2021 compared to its 2020 full-year expectation of $90M.The company said “recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operat...

Recent partner contracts and manufacturing investments have Captisol business operating at record high levels Continued clinical progress of Captisol-enabled drugs affirms the value of the proprietary technology Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) anno...

Ligand inks deal to acquire Taurus and xCella Biosciences Ligand Pharmaceuticals Inc. ( LGND ) reported that it has inked a deal to acquire two companies, xCella Biosciences Inc. and Taurus Biosciences. Both these companies are privately held and are expected to boost Ligand’s Omn...

Ligand Pharmaceuticals (NASDAQ: LGND ) acquired  two privately held companies that strengthen and complement its OmniAb ® technology platform. More news on: Ligand Pharmaceuticals Incorporated, Merger & acquisition news, Healthcare stocks news, Read more ...

The acquired technologies continue to position Ligand’s OmniAb as a best-in-class platform for antibody discovery Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen and complement its OmniAb ® te...